We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+13.87%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$257M
AUM Growth
+$29.3M
Cap. Flow
+$13.8M
Cap. Flow %
5.38%
Top 10 Hldgs %
63.16%
Holding
47
New
14
Increased
6
Reduced
6
Closed
13

Top Buys

Rank Stock Value
1
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$15.1M
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$11.8M
3
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$9.74M
4
RLYP
RELYPSA INC COM
RLYP
+$8.25M
5
ATRS
Antares Pharma, Inc.
ATRS
+$6.79M

Top Sells

Rank Stock Value
1
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$22.9M
2
CNXR
Connecture, Inc.
CNXR
+$15.2M
3
OFIX icon
Orthofix Medical
OFIX
+$10.8M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$7.07M
5
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$7M

Sector Composition

Rank Sector Weight
1 Healthcare 60.2%
2 Technology 16.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
PUT
Exelixis
EXEL
$13.3B
$2.8M 1.09%
+745,000
New +$2.42M
OREX
27
DELISTED
Orexigen Therapeutics, Inc.
OREX
$2.18M 0.85%
+44,000
New +$2.63M
DSCI
28
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2M 0.78%
280,000
-697,923
-71% -$5.25M
ENTA icon
29
Enanta Pharmaceuticals
ENTA
$366M
$1.57M 0.61%
35,000
-65,000
-65% -$2.53M
ATHX
30
CALL
DELISTED
Athersys, Inc. Common Stock
ATHX
$977K 0.38%
32,308
-900
-3% -$34.9K
ESPR
31
DELISTED
Esperion Therapeutics
ESPR
$687K 0.27%
+8,400
New +$822K
STRM
32
DELISTED
Streamline Health Solutions
STRM
$424K 0.17%
10,107
– –
ATHX
33
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$121K 0.05%
4,000
– –
BDSI
34
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$82K 0.03%
+10,300
New +$88.5K
EBS icon
35
Emergent Biosolutions
EBS
$373M
– –
-102,791
Closed -$2.96M
HRTX icon
36
Heron Therapeutics
HRTX
$93.9M
– –
-270,000
Closed -$3.93M
LITS
37
Lite Strategy Inc
LITS
$32.8M
– –
-2,613
Closed -$94K
OFIX icon
38
Orthofix Medical
OFIX
$477M
– –
-300,000
Closed -$10.8M
SSKN
39
DELISTED
Strata Skin Sciences
SSKN
– –
-11,392
Closed -$1.46M
VCYT icon
40
Veracyte
VCYT
$3.7B
– –
-68,158
Closed -$497K
ARAV
41
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-64,167
Closed -$7.07M
FRTX
42
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
– –
-269
Closed -$800K
BLCM
43
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-5,000
Closed -$1.16M
AMPE
44
PUT
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
– –
-1,405
Closed -$3.17M
SCMP
45
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-450,000
Closed -$7M
HPTX
46
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
– –
-500,000
Closed -$22.9M
OSIR
47
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
– –
-12,165
Closed -$214K
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2015 Portfolio in Review

As of Q2 2015, Great Point Partners held 47 positions worth $257M, up 13% from $227M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Great Point Partners deployed $13.8M of net new capital in Q2 2015, opening 14 new positions and adding to 6 existing holdings. Its largest new stake was Five Prime Therapeutics, Inc.: 678,595 shares worth $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 49% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Connecture, Inc., an estimated $15.2M trimmed.

  • Great Point Partners's largest Q2 2015 buy was Five Prime Therapeutics, Inc.: 678,595 shares worth $16.9M.
  • Great Point Partners added most to DYAX CORPORATION in Q2 2015, an estimated $6.28M increase.
  • Great Point Partners's biggest Q2 2015 reduction was Connecture, Inc., cutting an estimated $15.2M.
  • Great Point Partners fully exited HYPERION THERAPEUTICS INC COM STK (DE) in Q2 2015, selling an estimated $22.9M.
  • Great Point Partners's ten largest holdings make up 63% of its $257M portfolio in Q2 2015.
  • Great Point Partners opened 14 new positions and closed 13 in Q2 2015.
  • Great Point Partners's portfolio value rose 13% quarter-over-quarter to $257M.

Based on Great Point Partners's 13F filing for Q2 2015, filed 14 Aug 2015.